Andrew Mountain
Keele University
18 Papers
237 Citations
Andrew Mountain is an academic researcher from Keele University. The author has contributed to research in topics: Prodrug & Viral vector. The author has an hindex of 15, co-authored 18 publications. Previous affiliations of Andrew Mountain include University of Birmingham.
Chat about Author
Papers
Virus-directed enzyme prodrug therapy : intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer
Daniel H. Palmer,Vivien Mautner,Darius F. Mirza,Simon Oliff,Winald R. Gerritsen,Joost R.M. van der Sijp,Stefan G. Hubscher,Gary M. Reynolds,Sarah Bonney,Ratna Rajaratnam,Diana Hull,Mark Horne,John Ellis,Andrew Mountain,Simon Hill,Peter A. Harris,Peter F. Searle,Lawrence S. Young,Nicholas D. James,David J. Kerr +19 more
TL;DR: Direct intratumoral inoculation of CTL102 to patients with primary and secondary liver cancer is feasible and well tolerated and the high level of nitroreductase expression observed at 1 to 5 x 10(11) virus particles mandates further studies in patients with inoperable tumors who will receive CTL 102 and CB1954.
133
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy
Peter F. Searle,Ming-Jen Chen,Longqin Hu,Paul R. Race,Andrew L. Lovering,Jane I. Grove,Christopher P. Guise,Mansooreh Jaberipour,Nicholas D. James,Vivien Mautner,Lawrence S. Young,David J. Kerr,Andrew Mountain,Scott A. White,Eva I. Hyde +14 more
TL;DR: The prodrug CB1954 (5‐(aziridin‐1‐yl)‐2,4‐dinitrobenzamide) is activated by Escherichia coli nitroreductase (NTR) to a potent DNA‐crosslinking agent.
130
Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
Alistair Simpson Irvine,Peter K.E. Trinder,David Laughton,David Laughton,Helen Ketteringham,Ruth H. McDermott,Sophie C.H. Reid,Adrian M.R. Haines,Abdu Amir,Rhonda Husain,Rajeev Doshi,Lawrence S. Young,Andrew Mountain +12 more
TL;DR: The CL22 system is a fast and efficient alternative to viral vectors for engineering DCs for use in immunotherapy and research and protected mice from lethal challenge with tumor cells in an aggressive model of melanoma.
103
CL22 - a novel cationic peptide for efficient transfection of mammalian cells.
Adrian M.R. Haines,Alistair Simpson Irvine,Andrew Mountain,J. A. Charlesworth,N. Farrow,R. D. Husain,H. Hyde,H. Ketteringham,R. H. Mcdermott,A. F. Mulcahy,Tracey Mustoe,S. C. H. Reid,M. Rouquette,J. C. Shaw,D. R. Thatcher,J. H. Welsh,D. E. Williams,W. Zauner,Ross Owen Phillips +18 more
TL;DR: It is demonstrated that the superior transfection activity of CL22 compared with other DNA condensing peptides is conferred at a step after uptake of the complexes into cells, and it is shown that CL22–DNA complexes have transfections activity that is at least equivalent to the best available nonviral agents.
51
Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity.
Kai S. Lipinski,Steven Pelech,Andrew Mountain,Alistair Simpson Irvine,Robert Kraaij,Chris H. Bangma,Kingston H. G. Mills,Stephen Todryk,Stephen Todryk,Stephen Todryk +9 more
TL;DR: Gene-directed enzyme-prodrug therapy using nitroreductase (NTR), with efficient adenoviral delivery, and CB1954, is an effective means of directly killing tumours but an immune-mediated bystander effect remains an important product of GDEPT since it is often critical to the elimination of untransduced tumour cells.
21